Vanadium pentoxide (V 2 O 5 ) is a cause of occupational asthma and chronic bronchitis, yet the molecular mechanisms through which V 2 O 5 exerts its effects on cell function are unclear. In this study we investigated the potential of V 2 O 5 to activate the extracellular signal-regulated kinases 1 and 2 (ERK-1/2) in rat pulmonary myofibroblasts. Treatment of myofibroblasts with V 2 O 5 resulted in the activation of ERK-1/2, yet the inert metal titanium dioxide had no effect on ERK-1/2 activation. Metals are emerging as principal agents in air-pollution particles that cause adverse respiratory effects. Vanadium compounds in particular have been identified as a source of occupational bronchial asthma and bronchitis in individuals working in the petrochemical industry (1, 2). Vanadium-containing residual oil fly ash particles from the emissions of petrochemical plants cause lung inflammation and airway hyperresponsiveness in rats (3, 4). Moreover, vanadium-bearing emission source particles or urban particulate matter containing trace levels of vanadium upregulate the expression of a variety of inflammatory cytokines or their receptors in vitro (5, 6). We have previously reported that vanadium instilled intratracheally in rats causes airway remodeling that includes airway smoothmuscle thickening, mucous-cell metaplasia, and peribronchiolar fibrosis (7). The cellular and molecular mechanisms that mediate vanadium-induced airway injury are not well understood. However, increasing evidence indicates that vanadium could cause cellular stress by activating a variety of signal transduction pathways, including those leading to the phosphorylation of mitogen-activated protein (MAP) kinases (8-10).
Metals are emerging as principal agents in air-pollution particles that cause adverse respiratory effects. Vanadium compounds in particular have been identified as a source of occupational bronchial asthma and bronchitis in individuals working in the petrochemical industry (1, 2) . Vanadium-containing residual oil fly ash particles from the emissions of petrochemical plants cause lung inflammation and airway hyperresponsiveness in rats (3, 4) . Moreover, vanadium-bearing emission source particles or urban particulate matter containing trace levels of vanadium upregulate the expression of a variety of inflammatory cytokines or their receptors in vitro (5, 6) . We have previously reported that vanadium instilled intratracheally in rats causes airway remodeling that includes airway smoothmuscle thickening, mucous-cell metaplasia, and peribronchiolar fibrosis (7) . The cellular and molecular mechanisms that mediate vanadium-induced airway injury are not well understood. However, increasing evidence indicates that vanadium could cause cellular stress by activating a variety of signal transduction pathways, including those leading to the phosphorylation of mitogen-activated protein (MAP) kinases (8) (9) (10) .
MAP kinases are a family of serine/threonine kinases that regulate a diversity of cellular activities. Three major classes have been described: extracellular signal-regulated kinases (ERKs), Jun amino-terminal kinases (JNKs) (also known as stress-activated protein kinases), and p38 MAP kinases (reviewed in [11] [12] [13] . JNKs and p38 MAP kinases mediate signals in response to cytokines and environmental stress, whereas the ERK subtypes are classically recognized as key transducers in the signaling cascade mediating cell proliferation in response to growth factors such as platelet-derived growth factor (PDGF) and epidermal growth factor (EGF) (11) . Two major isoforms of ERK, p44 (ERK-1) and p42 (ERK-2), have been identified in mammalian systems (13) . A major pathway involved in ERK-1 and ERK-2 stimulation in a variety of cell types requires the sequential activation of Ras, Raf, and MAP kinase kinase (MEK) (12) . It is becoming increasingly clear that the ERK pathway, like p38 and JNK, is activated by environmental stress including reactive oxygen species (ROS) such as H 2 O 2 and transition metals including vanadium (14) (15) (16) .
Vanadium compounds have been reported to activate all three MAP kinase families (JNK, p38, and ERK), although the precise mechanism of activation of these MAP kinases remains unclear (8, 9) . Pervanadate has been reported to activate ERK-1/2 via phosphorylation of the EGF receptor (EGF-R), and the presumed mechanism of EGF-R activation is via competitive inhibition of protein tyrosine phosphatase (PTP) activity (8) . However, PTP inhibition may occur through oxidant-independent and oxidant-dependent mechanisms, depending on the vanadium compound. For example, vanadate is a competitive PTP inhibitor and inhibition is reversible with ethylenediaminetetraacetic acid (EDTA) (10) . In contrast, pervanadate (a complex of vanadate and H 2 O 2 ) inhibits by irreversibly oxidizing the catalytic cysteine of PTP (10) . The possible contribution of vanadium-generated ROS in mediating MAP kinase activation, either through PTP inhibition or an alternative mechanism, has not been investigated.
In this study we have investigated the mechanism of MAP kinase activation in rat pulmonary myofibroblasts by vanadium pentoxide (V 2 O 5 ), a largely insoluble form of vanadium present in ambient air pollution particles that has been associated with fibroproliferative lung disease (17) . Titanium dioxide (TiO 2 ), a metal that does not cause pulmonary disease in vivo , was used as a negative control of comparable particle diameter (18) . V 2 O 5 was a potent activator of ERK-1/2, whereas TiO 2 did not activate ERK-1/2. The EGF-R-specific tyrosine kinase inhibitor AG1478 blocked V 2 O 5 -induced ERK-1/2 activation, but surprisingly EGF-R was only weakly phosphorylated by V 2 O 5 as compared with activation of EGF-R by EGF. Instead, V 2 O 5 primarily caused tyrosine phosphorylation of a 115-kD protein (p115) that was immunoprecipitated by an anti-Src homology 2 PTP (SH-PTP2) antibody. Moreover, activation of p115 was inhibited by AG1478. V 2 O 5 -induced ERK-1/2 activation and p115 phosphorylation were blocked by the antioxidant N -acetyl-L -cysteine (NAC). These data support the idea that V 2 O 5 activates ERK-1/2 through an EGF-R signaling pathway that is initiated via the generation of ROS. ). An anti-ERK-1/2 that recognizes total cellular ERK (i.e., both activated and inactivated forms) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA). An anti-phospho-ERK-1/2 antibody that is specific for the activated forms of ERK-1/2 was purchased from Promega (Madison, WI). The phosphotyrosine monoclonal antibody (PY20) and antimouse immunoglobulin (Ig) G-horseradish peroxidase (HRP) were purchased from Transduction Laboratories (Lexington, KY). An anti-EGF-R polyclonal antibody, an anti-protein kinase (PK) C-␤ 1 antibody, and a polyclonal anti-SHPTP2 antibody-agarose conjugate were from Santa Cruz. NAC was from Sigma. Tyrphostin AG1478 was from Calbiochem (La Jolla, CA). The MEK-1 inhibitor PD98059 ([2-(2 Ј -amino-3 Ј -methoxyphenyl)-oxanapthalen-4-one]) was obtained from New England Biolabs, Inc. (Beverly, MA). The PKC inhibitors GF 109203X and Ro 31-8220 were from Calbiochem. Primary passage rat-lung myofibroblasts were isolated and characterized as described previously (18) .
Materials and Methods

Materials
Western Blotting
Confluent rat lung myofibroblasts in 75-cm 2 dishes were growtharrested in serum-free defined medium (SFDM) for 24 h, then treated with 10 g/cm 2 of V 2 O 5 or TiO 2 for 5 min to 2 h. The cells were washed twice with ice-cold phosphate-buffered saline (PBS) and scraped. The cell pellets were resuspended in a lysis buffer (50 mM N -2-hydroxyethylpiperazine-N Ј -ethane sulfonic acid [Hepes], 150 mM NaCl, 1% Triton X-100, 1 mM phenylmethylsulfonyl fluoride [PMSF] , and 20 g/ml aprotinin, leupeptin, and pepstatin) and clarified by centrifugation at 13,000 rpm for 10 min. The protein concentrations were determined by Bradford assay. A total of 20 g of protein from each sample was loaded on a 10 to 20% sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) gel. Separated proteins were then transferred to a nitrocellulose membrane and the membrane was blocked for 2 h at room temperature with 5% nonfat milk in Tris-buffered salineTween buffer (20 mM Tris, 500 mM NaCl, and 0.01% Tween 20). The membrane was then incubated with the anti-phospho-ERK1/2 antibody (1:1,000 dilution) at 4 Њ C overnight, followed by incubation for 2 h with a 1:2,000 dilution of HRP-conjugated antirabbit IgG. The immunoblot was visualized through enhanced chemiluminescence (Amersham, Arlington Heights, IL). The same blot was subsequently stripped at 50 Њ C for 30 min in a buffer containing 62.5 mM Tris (pH 6.7), 2% SDS, and 100 mM ␤ -mercaptoethanol. The stripped blots were reprobed with anti-ERK1/2, anti-PKC-␤ 1, or anti-phosphotyrosine (PY20).
EGF-R and SH-PTP2 Immunoprecipitation
Whole cell lysates were prepared as described in W ESTERN B LOT-TING . For EGF-R immunoprecipitation, cell lysates containing equal amounts of protein were incubated with 10 l (4 g) of anti-EGF-R polyclonal antibody at 4 Њ C overnight. A total of 20 l of protein-A agarose was then added to the lysates and incubated for 1 h. For immunoprecipitation of SH-PTP2, 2 l (4 g) of an anti-SH-PTP2 polyclonal antibody-agarose conjugate was added to each cell lysate and incubated overnight. The immune complex bound to agarose beads was pelleted by centrifugation and washed three times with lysate buffer. A total of 15 l of 5 ϫ SDS-PAGE loading buffer was added to the immunoprecipitates before electrophoresis and Western blotting for phosphotyrosine.
PHAS-1 Kinase Assay
ERK activity in cell lysates was measured as described previously (19) by phosphorylation of PHAS-1, a substrate for ERK-1/2 (20) . Briefly, confluent rat lung myofibroblasts in 75-cm 2 dishes were growth-arrested in SFDM for 24 h, then treated with 10 g/cm 2 of V 2 O 5 or TiO 2 for 5 min to 2 h. The cells were placed on ice, then washed twice with PBS and scraped off with 800 l of lysate buffer consisting of 50 mM Hepes, 150 mM NaCl, 1% Triton X-100, 1 mM PMSF, and 20 g/ml aprotinin, leupeptin, and pepstatin. Lysates were clarified by centrifugation at 13,000 rpm for 10 min and protein concentrations were determined by Bradford assay. Immunoprecipitation was performed by incubating 200 l of lysate with 2 g of anti-ERK antibody for 2 h, then adding 20 l of protein-A/agarose (Santa Cruz). After an overnight incubation at 0 to 4 Њ C with end-over-end mixing, the immune complex was recovered by centrifugation and washed three times with lysis buffer and once with 250 mM Hepes (pH 7.4), 10 mM MgCl 2 , and 200 M Na 3 VO 4 . Immune-complex kinase assays were performed using a MAP Kinase Assay Kit (Stratagene, La Jolla, CA). The ERK pellets were resuspended in Stratagene reaction buffer containing 120 g of PHAS-1 substrate along with 3-5 Ci [ ␥ -32 P]adenosine triphosphate in a final volume of 180 l. Kinase reactions took place for 30 min at room temperature and were stopped by adding 4 ϫ SDS-PAGE reducing sample buffer and boiling for 10 min. ERK-Phas samples were resolved on 4 to 20% PAGE gels, dried, and autoradiographed.
Results
Differential Activation of ERK-1/2 by V 2 O 5 and TiO 2 V 2 O 5 exposure stimulated activation of ERK-1/2 in rat pulmonary myofibroblasts as demonstrated by Western blotting using an antibody to the phosphorylated forms of ERK-1/2 ( Figure 1A ). In contrast, the inert metal TiO 2 did not activate ERK-1/2. The same blot was stripped and Western blotting was performed using an anti-ERK antibody that recognized total ERK-1/2 (activated and unactivated) to show equivalent amounts of MAP kinase in each lane ( Figure 1A) . To verify ERK-1/2 activity, immunoprecipitation was performed on cell lysates using the antibody raised against total ERK-1/2 and kinase assays were performed using PHAS-1 as a substrate ( Figure 1B ). These data clearly show that V 2 O 5 was a strong activator of ERK-1/2-induced phosphorylation of PHAS-1. Dose-response experiments using increasing concentrations of metal showed that 10 g/cm 2 of V 2 O 5 caused maximal activation of ERK-1/2, whereas 0.1 g/cm 2 V 2 O 5 did not activate ERK-1/2 and 1 g/cm 2 induced an approximate half-maximal response (data not shown). Figure 2B ). These data indicate that V 2 O 5 was not directly causing ERK-1/2 phosphorylation but was mediating MAP kinase activation via a sequential Raf/MEK/ERK pathway. Because other investigators reported that ERK-1/2 activation by H 2 O 2 was PKC-dependent, we investigated the possible involvement of PKC in V 2 O 5 -induced ERK-1/2 activation. Phorbol 12-myristate 13-acetate (PMA) treatment is known to cause acute activation of conventional and novel PKCs (within 5 min), while depleting the level of these PKCs after prolonged (24 h) treatment (22) . Treatment of myofibroblasts with 1 M PMA strongly activated ERK-1/2 within 5 min ( Figure 3A) , demonstrating that ERK-1/2 can be activated via a PKC-dependent pathway in these cells. However, ERK-1/2 activation by V 2 O 5 was not affected by treatment with PMA for 24 h, which completely depleted levels of PKC-␤1 ( Figure 3B) . Further, pretreatment of myofibroblasts with specific inhibitors of conventional PKCs GF 109203X (100 M) and Ro (Figure 4A ). Western blotting with the PY20 phosphotyrosine antibody revealed that V 2 O 5 caused tyrosine phosphorylation of a protein with a molecular mass of 115 kD and to a lesser extent induced phosphorylation of a ‫ف‬ 66-kD protein (p66) ( Figure 4B ). The phosphorylation of both p115 and p66 were inhibited 60 to 70% by 100 M AG1478 ( Figure 4B) . Surprisingly, no detectable phosphorylation was observed at the molecular mass corresponding to the EGF-R (170 kD) ( Figure 4B ). However, immunoprecipitation with an EGF-R antibody followed by phosphotyrosine Western blotting revealed that EGF-R tyrosine phosphorylation did occur as a result of V 2 O 5 treatment, although the relative amount of phosphorylated EGF-R was Ͻ 5% of the amount of tyrosine phosphorylation observed in EGF-treated cells ( Figure 5A ). EGF also stimulated phosphorylation of 115-and 66-kD proteins ( Figure  5B ). EGF-R immunoprecipitation did not result in coimmunoprecipitation of either 115-or 66-kD phosphorylated proteins in either V 2 O 5 -or EGF-treated cells ( Figure 5A ). The 115-kD protein that was tyrosine phosphorylated after V 2 O 5 treatment or EGF stimulation was identified as an SH-PTP2-binding protein, inasmuch as this phosphoprotein was immunoprecipitated with a polyclonal anti-SH-PTP2 antibody ( Figure 5C ). Anti-SH-PTP2 did not coimmunoprecipitate the EGF-R. 
Activation of ERK-1/2 and Tyrosine
Discussion
In this report we extend what is known regarding the activation of MAP kinases by vanadium compounds and demonstrate that V 2 O 5 -induced ERK-1/2 phosphorylation in rat pulmonary myofibroblasts is oxidant-dependent. Moreover, we report for the first time that a vanadium compound induces tyrosine phosphorylation of an SH-PTP2-binding protein that appears to be a substrate for EGF-R tyrosine kinase and leads to downstream ERK-1/2 activation. Zhao and coworkers previously reported that pervanadate activation of ERK-1/2 was mediated at least in part through an EGF receptor tyrosine kinase-coupled and Ras-coupled pathway that led to downstream activation of Raf and MEK (8) . However, these investigators attributed pervanadate-induced ERK-1/2 activation to the well-known ability of certain vanadium compounds (e.g., vanadate) to act as competitive inhibitors of PTP, and they did not consider the role of oxidants. Also, the mechanism of EGF-R activation was not explored in this previous study.
A recent study by Huyer and colleagues showed that pervanadate and vanadate inhibit PTP activity through completely different mechanisms (10) . These investigators demonstrated that vanadate is a competitive inhibitor for PTP1B and that EDTA (a vanadate chelator) caused an immediate and complete reversal of PTP1B inhibition due to vanadate. In contrast, pervanadate (a general term for complexes formed between vanadate and H 2 O 2 ) inhibited PTP1B by irreversibly oxidizing the catalytic cysteine of PTP1B as determined by mass spectrometry (10). Because V 2 O 5 -induced ERK-1/2 activation and tyrosine phosphorylation of the 115-kD SH-PTP2-binding protein was blocked by pretreatment with NAC, our data support the hypothesis that V 2 O 5 inhibition of PTP requires ROS. Other investigators have reported that H 2 O 2 is sufficient to inhibit PTP activity (24) . Thus, the ROS-dependent mechanism of PTP inhibition by V 2 O 5 could be similar to PTP inactivation by pervanadate.
It is becoming increasingly clear that oxidation plays an important role in the phosphorylation of receptor tyrosine kinases. For example, the binding of EGF to the EGF-R extracellular domain transiently increases intracellular H 2 O 2 , which serves to inhibit PTP activity and thereby favors tyrosine phosphorylation of the EGF-R (25). Lee and coworkers reported that H 2 O 2 inactivated PTP1B in a reversible manner by oxidizing its catalytic site cysteine, and also suggested that inhibition of PTP by H 2 O 2 might be required for receptor tyrosine kinase activation by binding of the growth factor (23) . Further, interleukin-1␤ (26) and lysophosphatidic acid (27, 28) cause ERK activation via the generation of ROS. Cunnick and coworkers have suggested that ROS could act by inhibiting PTP activity rather than directly increasing the EGF receptor kinase activity in the lysophosphatidic acid-stimulated MAP kinase pathway (27) . PDGF signal transduction requires ROS, and ligand-induced autophosphorylation of the PDGF receptor is blocked by NAC (29, 30) . These studies provide evidence that ROS are likely essential for normal signaling events associated with receptor tyrosine kinases including EGF-R and PDGF-R. However, there is growing evidence that environmental factors can disrupt normal cellular signaling via the generation of ROS. For example, asbestos causes ERK activation in rat pleural mesothelial cells via phosphorylation of the EGF-R, and this event appears to be mediated by oxidants (31) . Moreover, the addition of H 2 O 2 to cultured NIH 3T3 cells strongly activates ERK-1/2 and this is blocked by an EGF-R tyrosine kinase inhibitor (14) , and H 2 O 2 has been reported to stimulate phosphorylation of the EGF-R in A549 lung epithelial cells (32) . Thus, the EGF-R appears to be a central target for activation of MAP kinase by variety of environmental factors that generate oxidative stress.
Our data indicate that the EGF-R is involved in V 2 O 5 -induced ERK-1/2 activation. Tyrosine phosphorylation of EGF-R was detected after treatment with V 2 O 5 , and AG1478 (an inhibitor of EGF-R tyrosine kinase activity) blocked ERK-1/2 activation by V 2 O 5 . However, the major phospho-protein detected by phosphotyrosine Western blotting of V 2 O 5 -treated cell lysates was a 115-kD protein rather than the 170-kD EGF-R. We identified p115 as SH-PTP2-binding because this protein was immunoprecipitated by an anti-SH-PTP2 antibody. We further showed that p115 was an EGF-R substrate, inasmuch as AG1478 blocked ‫ف‬ 70% of V 2 O 5 -induced p115 tyrosine phosphorylation. Moreover, we showed that EGF treatment induced tyrosine phosphorylation of a 115-kD protein in addition to the 170-kD EGF-R.
Several groups have shown that expression of catalytically inactive SH-PTP2 results in the hyperphosphorylation of 115-to 120-kD proteins (33) (34) (35) . Yamauchi and Pessin observed a 115-kD protein in NIH 3T3 cells expressing high levels of the human EGF-R (3T3/ER) that was tyrosine-phosphorylated after EGF stimulation, and they identified the p115 in 3T3/ER cells as an SH-PTP2-binding protein (33) . These investigators found that immunoprecipitation of p115 by anti-SH-PTP2 did not coimmunoprecipitate the EGF-R, suggesting that only a small fraction of SH-PTP2 associates with the EGF receptor and that p115 is the major SH-PTP2-binding protein in EGFstimulated cells. A recent study by Frearson and Alexander showed that inactive SHP-2 (i.e., SH-PTP2) was targeted to the cell membrane in Jurkat T cells, resulting in a selective increase in tyrosine phosphorylation of three membrane-associated candidate SHP-2 substrates, one of which was a 110-kD protein, and this association was critical to linking SHP-2 to the Ras/MAP kinase pathway (36) . In the present study, our data support the hypothesis that Figure 5A ). Therefore, in this experiment the same blot was stripped and Western blotting was performed with an anti-EGF-R antibody, which verified the presence of EGF-R in all samples.
p115 is a SH-PTP2-binding protein and EGF-R substrate in V 2 O 5 -stimulated myofibroblasts that plays a major role in MAP kinase activation.
In contrast to some other studies of H 2 O 2 -induced ERK activation that reported a dependence on PKC (15), we clearly showed that depletion of conventional PKC activity by 24 h pretreatment with PMA did not inhibit V 2 O 5 -induced ERK-1/2 activation. In our experiments, ERK was activated by PMA within 5 min, and because PMA has been demonstrated to rapidly activate PKC (22) , this showed that PKC could mediate phosphorylation of ERK-1/2 in our system. However, chronic 24 h treatment by PMA depletes conventional and novel isozymes of PKC (22) , and in our hands this treatment had no effect on V 2 O 5 -induced ERK activation. In addition, we demonstrated that inhibitors of conventional PKCs GF 109203X and Ro 31-8220 did not block V 2 O 5 activation of ERK. Although PMA depletes conventional and novel isozymes of PKC, it does not deplete the atypical isozymes PKC-and PKC-. In fact, Liao and coworkers recently reported that angiotensin II activation of ERK-1/2 in vascular smoothmuscle cells is mediated by PKC- (37) . Therefore, we cannot rule out these PMA-insensitive, atypical PKC isozymes as mediators of V 2 O 5 -induced ERK-1/2 activation.
The role of V 2 O 5 -induced MAP kinase activation in the progression of fibroproliferative lung disease in vivo is unknown. The finding that an EGF-R signaling pathway is activated by V 2 O 5 in vitro is intriguing, inasmuch as we recently reported that administration of a tyrosine kinase inhibitor specific for the EGF-R (AG1478) prevents V 2 O 5 -induced pulmonary fibrosis in rats in vivo (38) . It is unclear whether the in vivo delivery of AG1478 inhibits the progression of fibrosis by simply blocking autophosphorylation of the EGF-R and subsequent mitogenesis of connective tissue cells stimulated by endogenous EGF-R ligands (i.e., EGF, transforming growth factor-␣, heparinbinding EGF), or whether V 2 O 5 exposure directly induces EGF-R phosphorylation and MAP kinase activation that results in increased connective tissue cell proliferation in the absence of endogenous EGF-R ligands.
In summary, we have shown that V 2 O 5 -induced MAP kinase activation is oxidant-dependent and requires components of an EGF-R signaling cascade. Importantly, we show for the first time that the major tyrosine-phosphorylated EGF-R substrate in vanadium-treated cells is a 115-kD SH-PTP2-binding protein that appears to play a role in ERK-1/2 activation. Further study is required to address the consequence of EGF-R signaling and subsequent MAP kinase activation to cell survival or cell death after exposure to metals that generate oxidative stress.
